MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor

Cancer Research

Volumn 70, Issue 4, 2010, Pages 1524-1533

  Pan, Bo Sheng ^a   Chan, Grace K Y ^a   Chenard, Melissa ^a   Chi, An ^a   Davis, Lenora J ^a   Deshmukh, Sujal V ^a   Gibbs, Jackson B ^a   Gil, Susana ^a   Hang, Gaozhen ^a   Hatch, Harold ^a   Jewell, James P ^a   Kariv, Ilona ^a   Katz, Jason D ^a   Kunii, Kaiko ^a   Lu, Wei ^a   Lutterbach, Bart A ^a   Paweletz, Cloud P ^a   Qu, Xianlu ^a   Reilly, John F ^a   Szewczak, Alexander A ^a   Zeng, Qinwen ^a   Kohl, Nancy E ^a   Dinsmore, Christopher J ^a   more..

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; FIBROBLAST GROWTH FACTOR RECEPTOR; MK 2461; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOTRANSFERASE INHIBITOR; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN KINASE B; RAS PROTEIN; SCATTER FACTOR; SCATTER FACTOR RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ARTICLE; AUTOPHOSPHORYLATION; CANCER CELL CULTURE; CANCER INHIBITION; CANCER THERAPY; CELL DIFFERENTIATION; CELL MIGRATION; CELL STRAIN 3T3; DRUG MECHANISM; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG TARGETING; ENZYME ACTIVATION; FIBROBLAST; GENE AMPLIFICATION; GENOMICS; IC 50; IN VITRO STUDY; INJECTION; MITOGENESIS; MOUSE; MUTANT; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; STOMACH CANCER; TUMOR CELL; TUMOR CELL LINE; TUMOR VOLUME; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; CELLS, CULTURED; DOGS; DRUG DELIVERY SYSTEMS; ENZYME ACTIVATION; FEMALE; HAPLORHINI; HUMANS; MICE; MICE, NUDE; NEOPLASMS; NIH 3T3 CELLS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-MET; SUBSTRATE SPECIFICITY; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 76749097199     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-09-2541     Document Type: Article

References (48)

1. Longati P, Bardelli A, Ponzetto C, Naldini L, Comoglio PM. Tyrosines1234-1235 are critical for activation of the tyrosine kinase encoded by the MET proto-oncogene (HGF receptor). Oncogene 1994;9:49-57.
2. Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF. Met, metastasis, motility and more. Nat Rev Mol Cell Biol 2003;4:915-25.
3. Benvenuti S, Comoglio PM. The MET receptor tyrosine kinase in invasion and metastasis. J Cell Physiol 2007;213:316-25.
4. Ponzetto C, Bardelli A, Zhen Z, et al. A multifunctional docking site mediates signaling and transformation by the hepatocyte growth factor/scatter factor receptor family. Cell 1994;77:261-71.
5. Brinkmann V, Foroutan H, Sachs M, Weidner KM, Birchmeier W. Hepatocyte growth factor/scatter factor induces a variety of tissue-specific morphogenic programs in epithelial cells. J Cell Biol 1995; 131:1573-86.
6. Bussolino F, Di Renzo MF, Ziche M, et al. Hepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell motility and growth. J Cell Biol 1992;119:629-41.
7. Gonzatti-Haces M, Seth A, Park M, Copeland T, Oroszlan S, Vande Woude GF. Characterization of the TPR-MET oncogene p65 and the MET protooncogene p140 protein-tyrosine kinases. Proc Natl Acad Sci U S A 1988;85:21-5.
8. Schmidt L, Duh FM, Chen F, et al. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet 1997;16:68-73.
9. Jeffers M, Fiscella M, Webb CP, Anver M, Koochekpour S, Vande Woude GF. The mutationally activated Met receptor mediates motility and metastasis. Proc Natl Acad Sci U S A 1998;95:14417-22.
10. Christensen JG, Burrows J, Salgia R. c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention. Cancer Lett 2005;225:1-26.
11. Smolen GA, Sordella R, Muir B, et al. Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752. Proc Natl Acad Sci U S A 2006; 103:2316-21.
12. Lutterbach B, Zeng Q, Davis LJ, et al. Lung cancer cell lines harboring MET gene amplification are dependent on Met for growth and survival. Cancer Res 2007;67:2081-8.
13. Engelman JA, Zejnullahu K, Mitsudomi T, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007;316:1039-43.
14. Bean J, Brennan C, Shih JY, et al. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci U S A 2007; 104:20932-7.
15. Zou HY, Li QH, Lee JH, et al. An orally available small-molecule inhibitor of c-met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms. Cancer Res 2007;67:4408-17.
16. Bellon SF, Kaplan-Lefko P, Yang Y, et al. c-Met inhibitors with novel binding mode show activity against several hereditary papillary renal cell carcinoma-related mutations. J Biol Chem 2008;283:2675-83.
17. Zhang YH, Kaplan-Lefko PJ, Rex K, et al. Identification of a novel recepteur d'origine nantais/c-Met small-molecule kinase inhibitor with antitumor activity in vivo. Cancer Res 2008;68:6680-7.
18. Raeppel S, Claridge S, Saavedra O, et al. N-(3-fluoro-4-(2-arylthieno [3,2-b]pyridin-7-yloxy)phenyl)-2-oxo-3-phenylimidazolidine-1-carboxamides: a novel series of dual c-Met/VEGFR2 receptor tyrosine kinase inhibitors. Bioorg Med Chem Lett 2009;19:1323-8.
19. Schroeder GM, An Y, Cai Z-W, et al. Discovery of N-(4-(2-Amino-3- chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1, 2-dihydropyridine-3-carboxamide (BMS-777607), a selective and orally efficacious inhibitor of the Met kinase superfamily. J Med Chem 2009;52:1251-4.
20. Burgess T, Coxon A, Meyer S, et al. Fully human monoclonal antibodies to hepatocyte growth factor with therapeutic potential against hepatocyte growth factor/c-Met-dependent human tumors. Cancer Res 2006;66:1721-9.
21. Martens T, Schmidt NO, Eckerich C, et al. A novel one-armed anti-c-Met antibody inhibits glioblastoma growth in vivo. Clin Cancer Res 2006;12:6144-52.
22. Liu X,Yao W, NewtonRC,Scherle PA. Targeting the c-MET signaling pathway for cancer therapy. Expert Opin Investig Drugs 2008;17:997-1011.
23. Migliore C, Giordano S. Molecular cancer therapy: can our expectation be MET? Eur J Cancer 2008;44:641-51.
24. Park Y-W, Cummings RT, Wu L, et al. Homogeneous proximity tyrosine kinase assays: scintillation proximity assay versus homogeneous time-resolved fluorescence. Anal Biochem 1999;269:94-104.
25. Nordin H, Jungnelius M, Karlsson R, Karlsson OP. Kinetic studies of small molecule interactions with protein kinases using biosensor technology. Anal Biochem 2005;340:359-68.
26. Meng FY, Wiener MC, Sachs JR, et al. Quantitative analysis of complex peptide mixtures using FTMS and differential mass spectrometry. J Am Soc Mass Spectrom 2007;18:226-33.
27. Yates JR III, Morgan SF, Gatlin CL, Griffin PR, Eng JK. Method to compare collision-induced dissociation spectra of peptides: potential for library searching and subtractive analysis. Anal Chem 1998;70:3557-65.
28. Chan GK, Lutterbach BA, Pan BS, Kariv I, Szewczak AA. High-throughput analysis of HGF-stimulated cell scattering. J Biomol Screen 2008;13:847-54.
29. Yamaguchi H, Miki H, Takenawa T. Neural Wiskott-Aldrich syndrome protein is involved in hepatocyte growth factor-induced migration, invasion, and tubulogenesis of epithelial cells. Cancer Res 2002;62: 2503-9.
30. Berthou S, Aebersold DM, Schmidt LS, et al. The Met kinase inhibitor SU11274 exhibits a selective inhibition pattern toward different receptor mutated variants. Oncogene 2004;23:5387-93.
31. Timofeevski SL, Ryan K, Cui J, et al. Enzymatic characterization of c-Met receptor tyrosine kinase oncogenicmutants and kinetic studieswith aminopyridine and triazolopyrazine inhibitors. Biochemistry 2009;48:5339-49.
32. Kunii K, Davis L, Gorenstein J, et al. FGFR2-amplified gastric cancer cell lines require FGFR2 and Erbb3 signaling for growth and survival. Cancer Res 2008;68:2340-8.
33. Rikova K, Guo A, Zeng Q, et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 2007;131:1190-203.
34. Rafferty B, Maile P, Rigsby P, et al. International standards for hepatocyte growth factor/scatter factor: initial assessment of candidate materials and their evaluation by multicentre collaborative study. J Immunol Methods 2001;258:1-11.
35. Di Renzo MF, Poulsom R, Olivero M, et al. Expression of the Met/hepatocyte growth factor receptor in human pancreatic cancer. Cancer Res 1995;55:1129-38.
36. Rege-Cambrin G, Scaravaglio P, Carozzi F, et al. Karyotypic analysis of gastric carcinoma cell lines carrying an amplified c-met oncogene. Cancer Genet Cytogenet 1992;64:170-3.
37. Moffa AB, Ethier SP. Differential signal transduction of alternatively spliced FGFR2 variants expressed in human mammary epithelial cells. J Cell Physiol 2007;210:720-31.
38. Liu Y, Gray NS. Rational design of inhibitors that bind to inactive kinase conformations. Nat Chem Biol 2006;2:358-64.
39. Knight ZA, Shokat KM. Features of selective kinase inhibitors. Chem Biol 2005;12:621-37.
40. Blume-Jensen P, Hunter T. Oncogenic kinase signaling. Nature 2001;411:355-65.
41. Hubbard SR. Protein tyrosine kinases: autoregulation and small-molecule inhibition. Curr Opin Struct Biol 2002;12:735-41.
42. Hubbard SR. Juxtamembrane autoinhibition in receptor tyrosine kinases. Nat Rev Mol Cell Biol 2004;5:464-71.
43. Wang W, Marimuthu A, Tsai J, et al. Structural characterization of autoinhibited c-Met kinase produced by coexpression in bacteria with phosphatase. Proc Natl Acad Sci U S A 2006;103:3563-8.
44. Atwell S, Adams JM, Badger J, et al. A novel mode of Gleevec binding is revealed by the structure of spleen tyrosine kinase. J Biol Chem 2004;279:55827-32.
45. Hubbard SR, Miller WT. Receptor tyrosine kinases: mechanisms of activation and signaling. Curr Opin Cell Biol 2007;19:117-23.
46. Nouaille S, Blanquart C, Zilberfarb V, et al. Interaction with Grb14 results in site-specific regulation of tyrosine phosphorylation of the insulin receptor. EMBO Rep 2006;7:512-8.
47. Nakajima M, Sawada H, Yamada Y, et al. The prognostic significance of amplification and overexpression of c-met and c-erb B-2 in human gastric carcinomas. Cancer 1999;85:1894-902.
48. Hattori Y, Itoh H, Uchino S, et al. Immunohistochemical detection of K-sam protein in stomach cancer. Clin Cancer Res 1996;2:1373-81.